INTRODUCTION
============

*Clostridium difficile* is a gram-positive, anaerobic bacterium that produces pathogenic toxins A and B. *C. difficile* infection (CDI) is the leading cause of nosocomial infectious diarrhea and is associated with substantial morbidity and mortality. The past decade has witnessed a rise in the incidence and severity of CDI in Western countries, as well as in Korea.[@B1][@B2][@B3][@B4]

The increased incidence and severity of CDI is even more pronounced in patients with IBD when compared to the general population.[@B5][@B6] A previous study evaluating the incidence of CDI in hospitalized patients in Canada reported that the CDI incidence in patients with IBD was 4.8%, whereas incidence in the general population was 0.45%.[@B7] In particular, patients with UC appear to be at higher risk of CDI than those with CD.[@B7][@B8][@B9] *C. difficile* is found in 3% to 24% of patients with active UC, and CDI is implicated in 5% of hospital admissions for UC.[@B5][@B7][@B9]

Furthermore, the presence of CDI in patients with UC is associated with increased mortality, length of hospital stay, and risk of colectomy.[@B5][@B10][@B11][@B12] Studies across Korea have reported that CDI is associated with a nearly 4-fold higher risk of acute mortality in hospitalized patients with UC.[@B7] Previous studies also have demonstrated increased length of hospital stays and a higher colectomy risk in patients with UC and CDI than in those without CDI.[@B5][@B11] Therefore, detecting CDI early is critical for initiating effective treatment in vulnerable patients, particularly those with UC.

Despite our understanding of the risk of CDI in patients with UC, no data are available to assess the prevalence of CDI in Korean patients with UC. A previous nationwide study in Korea did not find any patients with CDI and comorbid UC.[@B13] Therefore, we sought to investigate the prevalence and clinical outcome of CDI in the hospitalized UC patients with flare-up.

METHODS
=======

1. Study Design and Subjects
----------------------------

A prospective, multicenter, observational study was carried out from January 2014 to December 2015 in all consecutive patients with UC admitted because of disease flare-up. All patients had been diagnosed with UC based on clinical, endoscopic, and histological criteria.[@B14] Clinical UC disease activity was determined using the Mayo scoring system.[@B15] This study was conducted after institutional review board approval from all participating hospitals had been obtained. The informed consent was obtained from all subjects.

2. Definition and Clinical Outcomes of CDI
------------------------------------------

CDI was defined as a positive result on any of the following tests: *C. difficile* toxin A and/or B by enzyme immunoassay (Ridascreen; Biopharm, Darmstadt, Germany); real-time PCR (RT-PCR) of toxin genes; and endoscopic findings, such as multiple whitish or yellowish plaques, consistent with pseudomembranous colitis (PubMed Central \[PMC\]).

The impact of CDI was evaluated by assessing colectomy rate, inpatient mortality, and length of hospital stay.

3. Statistical Analysis
-----------------------

All statistical analyses were performed using SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as mean±SD and analyzed using independent sample *t*-tests, whereas categorical variables were expressed as numbers and analyzed using the chi-square or Fisher exact test. *P*-values \<0.05 were considered to be significant.

RESULTS
=======

1. Prevalence of CDI and Clinical Characteristics of Patients with and without CDI
----------------------------------------------------------------------------------

The demographic and clinical characteristics of patients with and without CDI are summarized in [Table 1](#T1){ref-type="table"}. During the study period, 81 patients were hospitalized because of a UC flare-up. The mean patient age was 39.6 years, and mean disease duration was 3.4 years. The extent of disease was proctitis in 8 patients (9.9%), left-sided colitis in 23 (28.4%), and extensive colitis in 50 patients (61.7%). Twenty-three patients (28.4%) were receiving anti-tumor necrosis factor (anti-TNF) therapy (infliximab or adalimumab) and 45.7% of patients were receiving systemic corticosteroids. CDI was detected in 8 of the 81 patients (9.9%) with a UC flare-up. Of the 8 patients with CDI, 6 (75.0%) were being treated with systemic corticosteroids and 4 (50.0%) were receiving anti-TNF therapy. Three patients (37.5%) had a history of antibiotic use within 30 days. There were no significant differences in age, sex, Charlson comorbidity index and medication history including antibiotics, probiotics, histamine2 receptor blocker and proton pump inhibitor between the 2 groups.

2. Diagnostic Tests for CDI
---------------------------

[Table 2](#T2){ref-type="table"} shows the diagnostic tests used to detect CDI and the clinical outcomes of patients with both UC and CDI. Among 81 patients, enzyme immunoassay was performed in 81 patients, PCR in 60 patients, and endoscopy was performed in 81 patients. All tests were performed within 3 days after admission. The enzyme immunoassay was positive in 3 of 8 patients, and PCR was positive in 5 of 7. Four patients had PCR-positive results for stool sample, but a negative enzyme immunoassay result. Endoscopy was performed in all patients with CDI, and only 1 patient demonstrated typical endoscopic findings of PubMed Central. The sensitivity of PCR was higher than that of other methods ([Table 3](#T3){ref-type="table"}).

3. Clinical Outcomes of Patients with CDI
-----------------------------------------

All patients with CDI were treated with oral metronidazole or vancomycin. All patients with CDI who had been admitted for a UC flare-up were discharged after improving clinically, with the mean length of stay being 16 days. No differences in length of hospital stay (16.3 days vs. 15.2 days, *P*=0.16) was observed between the patients with and without CDI. Two patients without CDI (2.7%) had a colectomy, whereas no patients with CDI underwent colectomy (*P*=0.64).

DISCUSSION
==========

There is limited data available for the prevalence and clinical outcomes of UC patients with CDI in Asian countries including Korea. To the best of our knowledge, this is the first prospective study evaluating the prevalence and clinical outcomes of CDI in Asian UC patients who have different genetic and ethnic backgrounds, compared to Western countries.

This study detected CDI in 8 of 81 patients (9.9%) hospitalized with a UC flare-up. Considering the low prevalence of CDI in the general Korean population, this prevalence rate of CDI in patients with UC is relatively high.[@B1][@B4][@B16] Our results are in contrast with those of US studies reporting a high incidence of CDI (up to 29%) among hospitalized patients with IBD, but are similar to results of studies from European countries (3.6%--7.0%).[@B17][@B18][@B19][@B20] Possible explanations for this discrepancy include differences in microbiological techniques, and heterogeneity of the patient populations studied. In addition, many recent studies were retrospective in nature and used diagnostic codes, where miscoding could either underestimate or overestimate CDI prevalence. In addition, the availability of information could have been limited, as CDI might only have been assessed in selected patient groups for clinical reasons.[@B7][@B8][@B10][@B11]

Some previous studies have reported that CDI in patients with IBD may be associated with older age, steroid use, disease severity, and recent antibiotic therapy.[@B5][@B21] However, in this study, of the 8 patients with UC and CDI, only 3 (37.5%) were diagnosed with CDI while on antibiotic therapy. This suggests that antibiotics may play a less significant role in the development of CDI in patients with UC than in the general population, which is consistent with some other studies.[@B6] A retrospective study showed that 40% of CDI patients with IBD used antibiotics, whereas 69% of CDI patients without IBD used antibiotics.[@B6] A recent prospective study demonstrated that CDI is not associated with antibiotic use.[@B22] However, given the small sample size of patients with CDI, our findings should be interpreted with caution.

Several studies in Western countries have reported that the presence of CDI in patients with UC is associated with increased mortality, length of hospital stay, and colectomy risk.[@B5][@B10][@B11][@B12] A recent study in the United States reported increased mortality and colectomy risk in patients with CDI, particularly if they had UC as well.[@B11] Similarly, in Canada, CDI worsened the clinical outcomes of UC by increasing length of hospital stay and colectomy rate.[@B23] However, in contrast with these results from Western countries, CDI did not affect the clinical course of hospitalized Korean patients with UC in our study. Similarly, the severity of CDI in the general Korean population is lower than that in Western countries, which may be because of lower prevalence of a hypervirulent strain, compared with that in Western countries.[@B1][@B13] However, *C. difficile* ribotype 027, which is the hypervirulent strain, was reported for the first time in Korea in 2009.[@B24] Therefore, close attention to the increased prevalence and severity of CDI is needed, particularly in patients with risk factors, such as UC.

Owing to their shared symptoms, it is often difficult to distinguish CDI from an IBD exacerbation. There is no testing strategy is optimally sensitive and specific for diagnosing CDI in patients with UC, and no study has evaluated the diagnostic accuracy of CDI in patients with IBD. Toxin enzyme immunoassay is the most widely used diagnostic test because of the ease of use and objective interpretation. Endoscopy is also performed to assess disease activity or to detect pseudomembranes in patients with a UC flare-up when CDI is suspected. However, enzyme immunoassays have low sensitivity (60%--70%), suggesting that a missed diagnosis is possible.[@B25][@B26] In addition, pseudomembranes are infrequently seen in UC patients with CDI.[@B5][@B27] Previous studies demonstrated that only 9% of patients with IBD have pseudomembranes on sigmoidoscopy or colonoscopy.[@B28] Indeed, in our study, among the 4 PCR-positive patients, 3 (75%) had a negative enzyme immunoassay result, and only 1 had pseudomembranes on sigmoidoscopy. Therefore, PCR may offer an advantage over enzyme immunoassay or endoscopy in diagnosing CDI in patients with UC. However, positive PCR results should be interpreted with caution, given the possibility of false positive PCR results.

One of this study\'s strengths was that consecutive patients were enrolled prospectively. Most previous studies used retrospectively collected cases derived from diagnostic codes instead of microbiological tests. In addition, we performed PCR in most cases, which is the most sensitive method for diagnosing CDI, whereas previous studies diagnosed CDI by using toxin assay with a low sensitivity. Therefore, in this study, the overall prevalence of CDI in hospitalized patients with UC was relatively more precise.

There were several limitations to this study. First, the number of patients included was small. Second, only academic teaching hospitals participated in this study, and the subjects attending these hospitals tend to be more severely ill than patients from smaller hospitals. In addition, it is uncertain that patients with positive PCR results have CDI or are simply colonized. Therefore, further studies are warranted to determine whether patients with negative enzyme immunoassay results and positive PCR results should be treated or not. However, despite these limitations, this prospective study provides important data on the prevalence and clinical impact of CDI in Korean patients with a UC flare-up.

In conclusion, the prevalence of CDI in patients with a UC flare-up was not lower in Korea, compared to that in Western countries. Therefore, CDI should be checked in patients with a UC flare-up.[@B29] RT-PCR was the most sensitive assay method and should be considered a diagnostic test for CDI in patients with UC.[@B30]
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###### Demographics and Clinical Characteristics of Patients with and without *Clostridium difficile* Infection

![](ir-16-267-i001)

  Characteristic                            *C. difficile* positive (n=8)   *C. difficile* negative (n=73)   *P*-value
  ----------------------------------------- ------------------------------- -------------------------------- -----------
  Age (yr)                                  45.1±20.6                       38.9±16.5                        0.39
  Male sex                                  2 (25)                          38 (52)                          0.15
  Duration of disease (mo)                  29 (1--133)                     45 (0--246)                      0.60
  Extent of UC (%)                                                                                           0.82
   Proctitis                                0                               8 (11)                           
   Left-sided colitis                       3 (38)                          20 (27)                          
   Extensive colitis                        5 (63)                          45 (62)                          
  Disease activity (Mayo score)             9.6±3.0                         9.5±2.8                          0.78
  Medication (%)                                                                                             
   5-ASA                                    8 (100)                         66 (90)                          0.40
   Corticosteroids                          6 (75)                          31 (42)                          0.34
   Immunomodulators                         6 (75)                          30 (41)                          0.38
   Biologics                                4 (50)                          19 (26)                          0.18
   Proton pump inhibitor                    1 (13)                          10 (14)                          0.93
   Histamine2 receptor blocker              1 (13)                          7 (10)                           0.79
   Probiotics                               2 (25)                          12 (16)                          0.54
  Charlson comorbidity index                1.25±1.17                       0.71±1.15                        0.13
  White blood cell counts (10^9^ cells/L)   8.8±2.7                         9.5 ± 3.9                        0.71
  CRP (mg/dL)                               4.0±3.7                         4.2±5.8                          0.36
  Length of hospital stay (day)             16.3±6.3                        15.2±13.9                        0.16
  Colectomy rate (%)                        0                               2 (3)                            0.64

Values are presented as mean±SD, number (%), or median (range).

ASA, 5-aminosalicylic acid.

###### Summary of Patients with UC and a *Clostridium difficile* Infection (n=8)
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  Patient   Age/sex   Duration (mo)   Medication            Antibiotics within 30 day prior to admission   Enzyme immunoassay   RT-PCR     Endoscopy   Treatment       Outcome    Length of stay (day)
  --------- --------- --------------- --------------------- ---------------------------------------------- -------------------- ---------- ----------- --------------- ---------- ----------------------
  1         79/F      7               5-ASA, AZP            No                                             −                    \+         −           Metronidazole   Improved   16
  2         46/F      11              5-ASA, CS, AZP        No                                             −                    \+         −           Vancomycin      Improved   20
  3         64/M      4               5-ASA, CS, ADA        Yes                                            −                    \+         −           Metronidazole   Improved   24
  4         19/F      7               5-ASA                 No                                             \+                   −          −           Metronidazole   Improved   8
  5         59/F      19              5-ASA, CS, AZP, IFX   Yes                                            −                    \+         −           Metronidazole   Improved   23
  6         33/F      121             5-ASA, CS, AZP, IFX   No                                             \+                   \+         −           Metronidazole   Improved   7
  7         28/M      1               5-ASA                 No                                             \+                   Not done   −           Metronidazole   Improved   14
  8         33/F      59              5-ASA, CS, AZP, ADA   Yes                                            −                    −          \+          Metronidazole   Improved   18

RT-PCR, real time PCR; F, female; 5-ASA, 5-aminosalicylic acid; AZP, azathioprine; CS, corticosteroid; M, male; ADA, adalimumab; IFX, infliximab.

###### Utility of Various Tests for Detecting *Clostridium difficile* Infection in Patients with UC
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  Parameter                   Enzyme immunoassay (%)   RT-PCR (%)   Endoscopy (%)
  --------------------------- ------------------------ ------------ ---------------
  Sensitivity                 37.5                     71.4         12.5
  Specificity                 100                      100          100
  Positive predictive value   100                      100          100
  Negative predictive value   93.6                     96.4         91.3
  Diagnostic accuracy         93.8                     96.7         91.4

RT-PCR, real time PCR.
